ASCO Annual Meeting | Conference

Novel JAK Inhibitor Alleviates Key Myelofibrosis Symptoms

May 30th 2015

Patients with myelofibrosis achieved significantly better outcomes in spleen volume reduction and symptom control with the novel JAK2 inhibitor pacritinib compared with best available therapy.

Daratumumab Data Impresses in Myeloma, FDA Submission Expected

May 30th 2015

Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.

Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study

May 30th 2015

Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.

Phase III Data Show Nivolumab Improves Survival Across Lung Cancer Subtypes

May 29th 2015

Nivolumab has now been shown to have an overall survival benefit versus docetaxel in both nonsquamous and squamous non–small cell lung cancer.

Dr. Seiwert on Pembrolizumab in Head and Neck Cancer

May 29th 2015

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Study Opens Door for Nivolumab in HCC

May 29th 2015

Nivolumab generated antitumor responses in nearly 20% of patients with advanced HCC in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes.

Pembrolizumab Demonstrates "Remarkable Efficacy" in Advanced HNSCC

May 29th 2015

In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.

Mismatch Repair a Potential Biomarker for PD-1 Inhibition

May 29th 2015

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

Dr. Burris on the Impact of the ASCO Annual Meeting

May 28th 2015

Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

ASCO Offers Data Sharing to Help With Value Transition

May 28th 2015

PracticeNET is an initiative emerging from ASCO's Clinical Affairs Department designed to help practices learn from one another's successes as they move farther away from fee-for-service and toward increasingly cost-effective models of care.

ASCO Highlights Include Phase III Findings in Multiple Tumor Types

May 27th 2015

Findings from large, late-stage clinical trials in melanoma, non–small cell lung cancer, and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology Annual Meeting.

Elotuzumab Combo Delays Myeloma Progression in Phase III Trial

May 13th 2015

Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma.

Large Study Adds Clarity to Use of Docetaxel With Standard Care in Advanced, Hormone-Naïve Prostate Cancer

May 13th 2015

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Nicotinamide Reduces New Skin Cancers in Those at High Risk

May 13th 2015

For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.

Intensified Chemotherapy Extends EFS for Children With Wilms Tumor

May 13th 2015

Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.

Dr. Perez on a Genomic Analysis of the NCCTG N9831 Adjuvant Trastuzumab Trial

June 20th 2014

Edith A. Perez, MD, discusses a genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.

Dr. Patel on an Analysis of Olaparib and Cediranib for Ovarian Cancer

June 18th 2014

Jyoti D. Patel, MD, discusses a phase II trial that looked at olaparib in combination with cediranib versus olaparib alone in recurrent platinum-sensitive ovarian cancer.

Dr. Schlumberger Draws Conclusions From the SELECT Trial in Thyroid Cancer

June 17th 2014

Martin Schlumberger, MD, Institut Gustave Roussy, Villejuif Cedex, professor of oncology, University Paris-Sud, France, discusses the takeaway points for a community oncologist from the SELECT trial.

Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

June 10th 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.

Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC

June 10th 2014

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

NEXT PAGE
PREVIOUS PAGE
x